Novanta Inc. (NOVT) Stock Price & How to Invest

Last updated November 2026

Short answer

You can invest in Novanta (NOVT) by buying shares or fractional shares at any major broker, through a small-cap or mid-cap growth or industrial ETF that holds it, or as one holding in a thematic basket. Novanta is a precision technology company that supplies photonics, vision, and precision motion components and sub-systems to medical and advanced industrial OEMs. As of November 20, 2026 the shares closed at $105.28, down about 5% year to date and up about 6% over one year, for a market value of roughly $4.0 billion, after a 25% drop over the past month that followed third-quarter results and a slight cut to full-year adjusted EPS guidance.

NOVT stock price

As of 2026-11-20, Novanta Inc. (NOVT) last closed at $101.99, down 4.2% over the past year. Over the past 52 weeks it has traded between $101.99 and $168.75.

NOVT last close
$101.99
1 day
-11.22%
1 month
-27.12%
1 year
-4.24%
52-week range
$101.99 to $168.75
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Novanta Inc.'s investor relations page. Walnut is informational, not investment advice.

NOVT key stats

At $101.99 on November 20, 2026, Novanta Inc. (NOVT) has a market cap of $3.9B and a P/E of 77.3 on trailing earnings (23.9 on forward earnings).

Market cap
$3.9B
P/E (trailing)
77.3
P/E (forward)
23.9
EPS (trailing 12 months)
$1.32
Price to book
2.4
Beta
1.70

Market cap, P/E and yield are measured at the $101.99 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Novanta Inc. (NOVT)?

The last two weeks for Novanta Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • NOVT closed at $101.99 on November 20, 2026, down 14.2% over the past five trading days (from $118.88).
  • On November 9, 2026, Novanta Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
  • On November 9, 2026, Novanta Inc. filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Novanta Inc. (NOVT) latest quarter

Novanta reported revenue of $305 million for Q3 2026, up 23% from a year earlier (Novanta, Nov 9, 2026).

Revenue
$305 million
up 23% from a year earlier
Diluted EPS (GAAP)
$0.05
down 83% from a year earlier
Automation Enabling Technologies
$145 million
up 16% from a year earlier

Source: Novanta Q3 2026 results, Nov 9, 2026. Full earnings breakdown

What does Novanta Inc. (NOVT) do?

Novanta Inc. is a specialized technology company that designs and manufactures photonics, precision motion, and vision components and sub-systems, which it sells to original equipment manufacturers (OEMs) in medical and advanced industrial markets worldwide. Its products include laser scanning and beam-steering systems, precision motors and encoders, machine-vision components, radio-frequency and surgical technologies, and other embedded devices that go inside customers' larger machines. The company organizes itself into two reporting segments: Medical Solutions, which serves minimally invasive surgery, life sciences, and patient monitoring, and Automation Enabling Technologies, which serves robotics, industrial automation, laser materials processing, and semiconductor and electronics manufacturing. Medical end markets represent a bit over half of revenue and advanced industrial the rest.

Novanta grows through a mix of organic gains in its OEM franchises and a steady cadence of bolt-on acquisitions that add technology and expand its addressable market. The investment picture is that of a diversified precision-components compounder: modest single-digit organic growth in a typical year, higher reported growth when acquisitions are added, and expanding adjusted margins, all of which the market has historically rewarded with a premium valuation. The trade-off is that the stock's high price-to-earnings multiple makes it sensitive to any slowdown in medical or industrial capital spending, integration missteps, or margin pressure, so the shares can be volatile around earnings and macro shifts.

The 2026 numbers have supported the growth case on revenue. Second-quarter revenue (quarter ended July 3, 2026) was about $266 million, up roughly 10% from a year earlier, and adjusted EPS of $0.89 beat the ~$0.83 consensus. In the third quarter (ended October 2, 2026) Novanta closed Riverpoint Medical, which its CEO called the largest acquisition in the company's history, and revenue rose about 23% to $305 million against a ~$301 million consensus, with adjusted EPS of $1.05 against $0.97, customer bookings up 29% and backlog of $543 million. GAAP net income fell to about $2 million in the quarter, however, and management lowered its full-year adjusted EPS guidance to about $3.69 at the midpoint, with fourth-quarter revenue guided to about $309 million. The deal changed the balance sheet as well: cash stood near $149 million against about $894 million of debt at quarter end. Trailing revenue has reached about $1.09 billion. The shares fell after the report and closed at $105.28 on November 20, 2026, down about 25% over the month, about 5% for the year, and near the bottom of a $99 to $176 52-week range.

What's driving Novanta Inc. (NOVT)?

1. Medical Solutions demand.

The Medical Solutions segment, which serves minimally invasive surgery, life sciences instrumentation, and patient monitoring, is roughly half of revenue and a key growth engine. Novanta supplies embedded photonics, motion, and radio-frequency technologies to medical-device OEMs, giving it exposure to durable healthcare spending trends. Demand here tends to be less cyclical than industrial markets, which supports steadier revenue. The Riverpoint Medical acquisition, closed in Q3 2026, adds to this segment, and management said on the Q3 call that it is performing in line with expectations, with progress on operational synergies and a new product pipeline.

2. Automation and robotics.

The Automation Enabling Technologies segment sells precision motion, machine vision, and laser components into robotics, industrial automation, and laser materials processing. Novanta reported strong bookings growth with a book-to-bill ratio above 1.0 in early fiscal 2026, pointing to recovering order momentum, and it increasingly shows up in market commentary as a robotics and AI-automation supplier. This unit ties Novanta to long-run automation and reshoring themes, though it is more sensitive to the industrial capital-spending cycle.

3. Acquisitions and margin expansion.

Novanta has a long track record of bolt-on acquisitions that add proprietary technology, broaden its OEM relationships, and expand its addressable market, and in Q3 2026 it closed Riverpoint Medical, its largest deal to date. Management pairs this with a focus on adjusted EBITDA margin expansion and pricing discipline; Q3 adjusted EBITDA margin was about 26%, up about 290 basis points year over year. The balance sheet has shifted with the deal: about $149 million of cash against roughly $894 million of debt at the latest quarter, compared with about $719 million of cash and $286 million of debt a quarter earlier. Successful integration is central to the growth story, since much of the company's reported revenue growth in a given year can come from deals rather than pure organic gains.

4. Order momentum turning into revenue.

In its Q1 fiscal 2026 report, Novanta cited bookings up about 37% year over year and raised its full-year outlook. Revenue then grew about 10% in the second quarter and about 23% in the third, helped by Riverpoint, with Q3 bookings up 29% and backlog at $543 million. For the fourth quarter management guided revenue to about $309 million, and analysts expect full-year 2026 revenue near $1.14 billion rising to about $1.31 billion in 2027, with 2027 EPS estimates around $4.27. Whether that backlog converts into sustained organic growth, apart from acquired revenue, is the open question.

What are the risks to Novanta Inc. (NOVT)?

Novanta trades at a high price-to-earnings multiple (about 80x trailing and 25x forward as of November 2026), so any shortfall in growth or margins can drive sharp share-price moves: the shares fell about 3% right after Q3 results, which came with a small cut to full-year adjusted EPS guidance and fourth-quarter EBITDA guidance below expectations, and ended about 25% lower over the month to November 20, 2026. A large share of revenue comes from advanced industrial and semiconductor-adjacent markets that are cyclical and can slow quickly when customers cut capital spending. The company depends heavily on acquisitions for growth, which brings integration, goodwill, and balance-sheet risk if deals underperform; after Riverpoint, debt is about $894 million against about $149 million of cash, and GAAP profit margins are thin at about 5%, with Q3 GAAP net income of only about $2 million. Because Novanta sells components embedded inside OEM products, it has customer-concentration and design-win risk, and results can be pressured by tariffs, supply-chain costs, and foreign-exchange swings given its global manufacturing and sales footprint.

Is NOVT a buy or a sell?

We give no verdict on Novanta Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Medical Solutions demand. The Medical Solutions segment, which serves minimally invasive surgery, life sciences instrumentation, and patient monitoring, is roughly half of revenue and a key growth engine.

The case against. Novanta trades at a high price-to-earnings multiple (about 80x trailing and 25x forward as of November 2026), so any shortfall in growth or margins can drive sharp share-price moves: the shares fell about 3% right after Q3 results, which came with a small cut to full-year adjusted EPS guidance and fourth-quarter EBITDA guidance below expectations, and ended about 25% lower over the month to November 20, 2026.

Read the full bull and bear case on NOVT, including what would have to change to break either one. Walnut is not an investment adviser.

Has Novanta Inc. (NOVT) split its stock?

No. Novanta Inc. (NOVT) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Novanta Inc. (NOVT) valued?

Market cap, P/E and dividend yield at today's price are in the NOVT key stats above. The business figures below come from Novanta Inc.'s reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$1.09 billion
  • Q3 FY2026 revenue: ~$305 million (up ~23% YoY)
  • Q3 FY2026 adjusted EPS: ~$1.05 vs ~$0.97 consensus
  • Margins (gross / operating / net): ~44% / ~12% / ~5%
  • Net income (TTM): ~$53 million

As of November 2026: Novanta still trades at a rich valuation, with a trailing price-to-earnings ratio near 80x and a forward multiple around 25x, down from about 30x forward in October after the shares fell roughly 25% in a month. GAAP earnings are held down by acquisition-related amortization, deal costs and stock compensation, so the company and analysts emphasize adjusted EPS, which beat consensus again in Q3 at $1.05 against $0.97 even as full-year adjusted EPS guidance was trimmed to about $3.69. Net debt of roughly $745 million after the Riverpoint deal is now part of the valuation picture.

Which ETFs hold Novanta Inc. (NOVT)?

If you want NOVT exposure as part of a larger bundle, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

ETFName% in NOVTExpense ratio
ROBORobo Global Robotics and Automation Index ETF1.76%0.95%

Who competes with Novanta Inc. (NOVT)?

Photonics and laser component makers

Companies like Coherent, IPG Photonics, MKS Instruments, and Lumentum compete in lasers, photonics, and laser materials processing where Novanta sells scanning and beam-steering components. These firms are generally larger and often supply higher-power or system-level laser products, while Novanta focuses on embedded precision sub-systems for OEMs.

Precision motion and vision suppliers

In precision motors, encoders, and machine vision, Novanta competes with players such as Cognex, Keyence, and various motion-control specialists. These companies also target industrial automation, robotics, and inspection markets where reliability and precision are the basis of competition.

Medical-device technology suppliers

Within its Medical Solutions segment, Novanta competes with other component and sub-system suppliers to medical-device OEMs across minimally invasive surgery, life sciences, and patient monitoring. Here the contest is over design wins inside customers' instruments, regulatory-grade quality, and long-term OEM relationships.

What stocks are similar to Novanta Inc. (NOVT)?

Other names that sit close to NOVT: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Novanta Inc. (NOVT)

There are three common ways to get NOVT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (ROBO), which spreads the position across many companies. Or build it into a focused thematic portfolio, so NOVT sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where NOVT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Novanta Inc. (NOVT)

Novanta is a niche precision-technology supplier whose growth leans on medical and automation OEM demand plus acquisitions, now including Riverpoint Medical, the largest deal in its history. It beat third-quarter estimates on revenue up about 23%, but trimmed its full-year adjusted EPS outlook, took on debt for the deal, and saw the shares fall about 25% in a month; at roughly 80x trailing and 25x forward earnings the multiple still leaves little room for disappointment.

More on Novanta Inc. (NOVT)

Whether NOVT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is NOVT a buy or a sell?, and where the stock could go from here in the NOVT stock forecast.

For income investors, whether NOVT pays a dividend and how the payout looks is covered in does NOVT pay a dividend? And to weigh NOVT against a peer, read the full side-by-side comparisons: NOVT vs COHR and NOVT vs IPGP.

Wondering how NOVT fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Novanta Inc.

Ask Walnut's AI anything about NOVT and see how it fits what you own.

FAQ

What does Novanta do?

+

Novanta is a precision technology company that designs and manufactures photonics, precision motion, and vision components and sub-systems. It sells these to original equipment manufacturers in medical and advanced industrial markets, where its parts are embedded inside customers' larger machines and instruments.

What are Novanta's business segments?

+

Novanta reports two segments: Medical Solutions, which serves minimally invasive surgery, life sciences, and patient monitoring, and Automation Enabling Technologies, which serves robotics, industrial automation, laser materials processing, and electronics manufacturing. Medical end markets are a bit over half of revenue and advanced industrial the rest.

How much revenue does Novanta generate?

+

Novanta generates roughly $1.09 billion in trailing-twelve-month revenue as of November 2026. Its third-quarter fiscal 2026 revenue was about $305 million, up around 23% year over year with the Riverpoint Medical acquisition, after about $266 million in the second quarter. Analysts expect full-year 2026 revenue of roughly $1.14 billion and about $1.31 billion in 2027.

Does Novanta pay a dividend?

+

Novanta does not pay a regular dividend. The company reinvests its cash flow into research and development and bolt-on acquisitions to fund growth, so returns to shareholders have historically come from share-price appreciation rather than income.

Why is Novanta's P/E ratio so high?

+

Novanta's trailing price-to-earnings ratio sits near 80x as of November 2026 because GAAP earnings (about $1.32 per share over the last twelve months) are depressed by acquisition-related amortization, deal costs and stock-based compensation, and because the market has priced it as a durable, high-margin compounder. Its forward multiple, around 25x, is lower and analysts often focus on adjusted EPS.

Who are Novanta's main competitors?

+

Novanta competes with photonics and laser firms like Coherent, IPG Photonics, MKS Instruments, and Lumentum, with precision-motion and machine-vision players like Cognex and Keyence, and with other component suppliers to medical-device OEMs. Its niche is embedded precision sub-systems rather than full systems.

What are the main risks of investing in Novanta?

+

Key risks include a high valuation that magnifies any earnings disappointment, cyclical exposure to industrial and semiconductor capital spending, heavy reliance on acquisitions for growth, and customer-concentration and design-win risk since its products sit inside OEM machines. Tariffs, supply-chain costs, and currency swings can also pressure results.

How did Novanta do in its latest quarter?

+

For the third quarter of fiscal 2026 (ended October 2, 2026), Novanta reported revenue of about $305 million, up roughly 23% from a year earlier and ahead of a ~$301 million consensus, and adjusted EPS of $1.05 against a consensus near $0.97. Bookings rose 29% and backlog reached $543 million, and the company closed Riverpoint Medical, its largest acquisition. GAAP net income was only about $2 million, management lowered full-year adjusted EPS guidance to about $3.69 at the midpoint, and it guided fourth-quarter revenue to about $309 million.

What is Novanta's Riverpoint Medical acquisition?

+

Novanta closed the acquisition of Riverpoint Medical in its third quarter of fiscal 2026, and its CEO called it the largest acquisition in the company's history. On the Q3 call management said Riverpoint is performing in line with expectations. The deal helped lift Q3 revenue about 23% and moved the balance sheet to roughly $894 million of debt against about $149 million of cash.

How has NOVT stock performed in 2026?

+

As of the November 20, 2026 close at $105.28, Novanta shares were down about 5% year to date and up about 6% over the past year, after falling about 25% over the past month. The 52-week range runs from about $99 to $176, so the stock sits near its low after a volatile year. Walnut is not an investment adviser, and this describes past prices only.

How can I invest in Novanta stock?

+

Novanta trades on the Nasdaq under the ticker NOVT, so you can buy shares or fractional shares through any major brokerage. You can also gain exposure through mid-cap or industrial-technology ETFs that hold it, or by including it as one holding in a diversified thematic basket. Walnut is not an investment adviser, so consider your own goals and risk tolerance.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Novanta Inc.'s investor relations page or your broker before making investment decisions.